LogixX Pharma is dedicated to developing and accelerating access to medicines that improve the lives of patients suffering from rare and orphan diseases.
To deliver on this commitment to patients, LogixX Pharma :
- Combines innovation and lifecycle management in its current markets – developing and launching new therapeutics and stewarding its existing products – while also expanding into new geographical territories.
- Invests 15% of its annual turnover in the research, development and commercialisation of novel therapeutics, with the aim of speeding doctors’ and patients’ access to crucial treatments.
- Establishes collaborative partnerships by in-licensing products and cooperating on late-stage projects with complementary organisations, thus making best use of its extensive in-house capabilities, technologies and networks and bringing new therapies to market more quickly and economically.
Partnering with LogixX Pharma
LogixX Pharma is currently evaluating opportunities for in-licensing, partnership and acquisition. The treatments in question must offer a high degree of innovation and fulfil an unmet medical need.
If you would like to discuss potential collaborations further, please contact us.